COVID-19 Vaccine Effectiveness in Patients With Hematologic Malignancies: A Nationwide Cohort Study - Summary - MDSpire

COVID-19 Vaccine Effectiveness in Patients With Hematologic Malignancies: A Nationwide Cohort Study

  • By

  • Quincy Hofsink

  • Birgit I Lissenberg-Witte

  • Sabine Haggenburg

  • Abraham Goorhuis

  • Mette D Hazenberg

  • Caroline E Rutten

  • Paul den Tex

  • Elisabeth G E de Vries

  • Astrid A M van der Veldt

  • Jeanet M Kemmeren

  • Nicolette F de Keizer

  • Peter C Huijgens

  • Avinash G Dinmohamed

  • Annika van Roon

  • Joyce Pijpers

  • Caren van Roekel

  • Susan van den Hof

  • Susan J M Hahné

  • Brechje de Gier

  • Jarom Heijmans

  • Inger S Nijhof

  • October 14, 2025

  • 0 min

Share

Objective:

To identify specific determinants of SARS-CoV-2 infection outcomes and assess COVID-19 vaccine effectiveness in patients with hematologic malignancies.

Key Findings:
  • Patients with hematologic malignancies had the highest risk of severe COVID-19.
  • Vaccine effectiveness against severe COVID-19 in these patients was up to 74%, varying by vaccination number, variant period, and time since vaccination.
  • Risk of severe COVID-19 was highest in patients with recently diagnosed hematologic malignancies and declined over time, except for chronic cases.
  • Patients on specific tumor treatments had a higher risk of severe COVID-19, particularly those receiving CD38 and CD20 antibodies, proteasome inhibitors, and protein kinase inhibitors.
Interpretation:

COVID-19 vaccination significantly reduced the risk of severe outcomes in patients with hematologic malignancies, but they remained at higher risk compared to other groups, highlighting the need for ongoing monitoring and tailored public health strategies.

Limitations:
  • Observational hospitalizations were limited due to capacity issues during the pandemic, which may have affected the data.
  • Potential confounding factors related to testing behavior and vaccination practices may not have been fully accounted for, potentially skewing results.
Conclusion:

The study highlights the importance of vaccination in reducing severe COVID-19 risk in patients with hematologic malignancies and suggests the need for tailored prevention strategies, such as booster vaccinations and targeted health interventions.

Original Source(s)

COVID-19 Vaccine Effectiveness in Patients With Hematologic Malignancies: A Nationwide Cohort Study

  • by Quincy Hofsink, Birgit I Lissenberg-Witte, Sabine Haggenburg, Abraham Goorhuis, Mette D Hazenberg, Caroline E Rutten, Paul den Tex, Elisabeth G E de Vries, Astrid A M van der Veldt, Jeanet M Kemmeren, Nicolette F de Keizer, Peter C Huijgens, Avinash G Dinmohamed, Annika van Roon, Joyce Pijpers, Caren van Roekel, Susan van den Hof, Susan J M Hahné, Brechje de Gier, Jarom Heijmans, Inger S Nijhof

  • October 14, 2025

Related Content

Self-administered digital vaccination decision-aids in primary care: A pilot study of COVID-19 vaccination in Atlanta, GA

Antibiotics May Not Help Mild COVID

A retrospective cohort study of more than 520,000 hospitalized patients found no clinically meaningful improvement in deterioration or mortality with early treatment targeting community-acquired pneumonia.

Dynamic hyperinflammatory response assessment using HIC scores in COVID-19: application to a large series of patients receiving anakinra